Xcellerant Ventures
  • Portfolio
  • Team
  • About
  • Invest
  • News
  • Contact
Select Page
CRISPR 2.0: Kinder, Gentler, More Powerful Gene Editing

CRISPR 2.0: Kinder, Gentler, More Powerful Gene Editing

by Tiffany Youtchoko | Jun 1, 2024 | Portfolio Company News

Origionally posted on Genetic Engineering and Biotechnology News: https://www.genengnews.com/topics/genome-editing/crispr-2-0-kinder-gentler-more-powerful-gene-editing/   Scientists have worked tirelessly to develop ever more precise and efficient CRISPR-Cas...
Big Wins, Strategic Moves and Growth for Ross Bundy’s CRISPR QC and Gene Editing

Big Wins, Strategic Moves and Growth for Ross Bundy’s CRISPR QC and Gene Editing

by Xcellerant Ventures | Jan 28, 2024 | Portfolio Company News

Origionally posted on MSN.com: https://www.msn.com/en-us/news/other/big-wins-strategic-moves-and-growth-for-ross-bundy%E2%80%99s-crispr-qc-and-gene-editing/ar-BB1hnksW?disableErrorRedirect=true&infiniteContentCount=0 The field of CRISPR editing has reached a...
Why We Invested: CRISPR QC

Why We Invested: CRISPR QC

by Xcellerant Ventures | Jan 12, 2024 | Portfolio Company News, Xcellerant Ventures News

Why Xcellerant Ventures Invested in CRISPR QC The Xcellerant Venture’s team is proud to lead a Series A funding round for CRISPR QC, the San Diego-based biotechnology company that has developed the world’s first and only CRISPR Analytics Platform.  This platform...
Xcellerant Ventures Ends First Year with 10th Investment, Leading CRISPR QC’s $10 Million Series A Round

Xcellerant Ventures Ends First Year with 10th Investment, Leading CRISPR QC’s $10 Million Series A Round

by Xcellerant Ventures | Jan 6, 2024 | Xcellerant Ventures News

Origionally posted on Business Wire: https://www.businesswire.com/news/home/20240105587000/en/Xcellerant-Ventures-Ends-First-Year-with-10th-Investment-Leading-CRISPR-QC%E2%80%99s-10-Million-Series-A-Round SCOTTSDALE, Ariz.–(BUSINESS WIRE)–Xcellerant...
Xcellerant Ventures Backs CRISPR QC in Series A and Commercial Expansion

Xcellerant Ventures Backs CRISPR QC in Series A and Commercial Expansion

by Xcellerant Ventures | Jan 5, 2024 | Portfolio Company News

Originally posted on Business Wire: https://www.businesswire.com/news/home/20240104480597/en/Xcellerant-Ventures-Backs-CRISPR-QC-in-Series-A-and-Commercial-Expansion SAN DIEGO–(BUSINESS WIRE)–CRISPR QC, a biotechnology start-up based in San Diego, is...
« Older Entries
Next Entries »

Recent Posts

  • TruLite Health Partners with Lee Health to Elevate Health Equity Strategy
  • TruLite Health Selected for Microsoft Pegasus Program
  • Xcellerant Ventures Leads DeepLook Medical’s Series A Round
  • DeepLook Medical’s DL Precise™ improved the performance of the breast imaging department with 12% favorable change in recall rates
  • Feasibility Study Evaluates Potential of Digital Health Platform to Help Patients Manage Prostate Cancer Symptoms

Recent Comments

No comments to show.
  • Portfolio
  • Team
  • About
  • Invest
  • News
  • Contact
  • Privacy Policy
© Xcellerant Ventures 2023